Efficacy and tolerability of rivastigmine patch therapy in patients with mild-to-moderate Alzheimer's dementia associated with minimal and moderate ischemic white matter hyperintensities: A multicenter prospective open-label clinical trial.
Kyung Won ParkEun-Joo KimHyun Jeong HanYong S ShimJae C KwonBon D KuKee Hyung ParkHyon-Ah YiKwang K KimDong Won YangHo-Won LeeHeeyoung KangOh Dae KwonSangYun KimJae-Hyeok LeeEun Joo ChungSang-Won ParkMee Young ParkBora YoonByeong C KimSang Won SeoSeong Hye ChoiPublished in: PloS one (2017)
ClinicalTrials.gov NCT01380288.
Keyphrases
- open label
- clinical trial
- white matter
- phase ii
- double blind
- phase iii
- phase ii study
- mild cognitive impairment
- study protocol
- cognitive decline
- high intensity
- multiple sclerosis
- cognitive impairment
- ischemia reperfusion injury
- randomized controlled trial
- placebo controlled
- squamous cell carcinoma
- radiation therapy
- cerebral ischemia
- cell therapy